Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: Maria Lycke Clear advanced filters

  • In this Review, Khalil et al. consider how technological advances have enabled the detection of neurofilament proteins in the blood, and discuss how these proteins consequently have the potential to be easily measured biomarkers of neuroaxonal injury in various neurological conditions.

    • Michael Khalil
    • Charlotte E. Teunissen
    • Jens Kuhle
    Reviews
    Nature Reviews Neurology
    Volume: 14, P: 577-589

  • Moskov et al. explored over 5400 blood protein biomarkers in relation to separating malign from benign ovarian tumours in two cohorts of symptomatic women. The study detected and validated many individual markers and developed a test based on eight biomarkers that showed excellent performance in classifying patients regardless of tumor type.

    • Mikaela Moskov
    • Julia Hedlund Lindberg
    • Stefan Enroth
    ResearchOpen Access
    Communications Medicine
    Volume: 5, P: 1-12

  • The International Multiple Sclerosis Genetics Consortium reports the discovery of 48 new susceptibility variants for multiple sclerosis through targeted follow-up of immune-related loci. They also report fine mapping of association signals at established susceptibility loci and provide insights into the immune system processes underlying this disease.

    • Ashley H Beecham
    • Nikolaos A Patsopoulos
    • Jacob L McCauley
    Research
    Nature Genetics
    Volume: 45, P: 1353-1360

  • Enroth et al. validate their previously developed 11-biomarker plasma protein-based risk-score for distinguishing benign vs. malignant ovarian tumors. The risk score is found to be informative of treatment outcome and predictive of 5-year survival.

    • Stefan Enroth
    • Emma Ivansson
    • Ulf Gyllensten
    ResearchOpen Access
    Communications Medicine
    Volume: 2, P: 1-13

  • Stefan Enroth et al. identify an 11 plasma protein signature that accurately distinguishes between ovarian cancer and benign tumors. The signature was identified after measuring 593 plasma proteins in three cohorts and could be used in the future to improve diagnosis or identify women who should be referred to a specialist.

    • Stefan Enroth
    • Malin Berggrund
    • Ulf Gyllensten
    ResearchOpen Access
    Communications Biology
    Volume: 2, P: 1-12